Due diligence

Vivodiem and its partners provide due diligence assessments in all phases of drug discovery and development from target identification to drug submission.

All partners have at least 10 years experience in pharmaceutical R&D in top-10 US or European companies.

We cover most areas of drug discovery and development: preclinical pharmacology, CM&C, ADME, toxicology, clinical development, statistics, quality, regulatory, intellectual property.

The due diligence team can be assembled very rapidly.  The team delivers a pre-diligence summary report based on available data, organises a 1- or 2-day visit at the research facility, provides post-diligence first impression immediately after the visit, and a full report within one or two weeks of the visit.

The due diligence assessment report contains a high level summary, a SWOT analysis, and a detailed data analysis for each drug development area.